HopeStage
Back to all studies
CompletedNCT00234377

Switching from other antipsychotics to extended-release quetiapine

About this titleRead the official source — NCT00234377
Medication studyAges 18–65Multiple countriesSchizophrenia
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
Vancouver and 26 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateNovember 2004
Recruitment status
Completed
Enrollment listed in the registry
550
Sponsor
AstraZeneca
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
Canada, Finland, Germany, ...
Age range
From 18 Years to 65 Years
Official registry ID
NCT00234377
Official title
Show the full official title

A 12-week International, Multicenter, Open Label, Non-comparative Study to Evaluate the Feasibility of Switching Any Antipsychotic Treatment to Sustained-release Quetiapine Fumarate (SEROQUEL®) in Patients With Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Vancouver, Canada · Aurora, Canada · Burlington, Canada

21 more locations
  • Mississauga, Canada
  • Orléans, Canada
  • Toronto, Canada
  • Québec, Canada
  • Saint-Laurent, Canada
  • Sherbrooke, Canada
  • Prince Albert, Canada
  • Helsinki, Finland
  • Mikkeli, Finland
  • Turku, Finland
  • München, Germany
  • Göttingen, Germany
  • Aachen, Germany
  • Saarbrücken, Germany
  • Halle, Germany
  • Homburg, Germany
  • Jena, Germany
  • Budapest, Hungary
  • Debrecen, Hungary
  • Gyula, Hungary
  • Székesfehérvár, Hungary

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is AstraZeneca.

Did this study involve medication?

Yes. The study involved medication, including Seroquel SR.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies